the details of EC-LNI status before and after NAC. Therefore, this issue should be investigated in the future study.Thirdly, adjuvant therapy is not routinely conducted for patients who underwent curative surgery following NAC in our institution. Meanwhile, mild chemotherapies including taxane (PTX) or S-1 were used as an adjuvant chemotherapy particularly for those with high number of positive LNs (ypN2-3), if the general condition of the patient allows. However, given the results of our study as shown in Fig. 3F, adjuvant therapy should also be considered for nonresponders in terms of total LN regression grade, even if they had small number of pathologically-positive LNs (ypN0-1). Prospective study would be necessary to clarify this issue in the future.Lastly, we appreciated kindly pointing out a type error in the abstract section in the present article. Accordingly, we will correct the sentence from ''Multivariate analysis for recurrence-free survival (RFS) revealed that LN regression grade [hazard ratio (HR) ¼ 2.25, P < 0.001], ypT (HR ¼ 1.65, P ¼ 0.005), and ypT (HR ¼ 1.62, P ¼ 0.004) were independent prognostic factors'' to ''Multivariate analysis for recurrence-free survival (RFS) revealed that LN regression grade [hazard ratio (HR) ¼ 2.25, P < 0.001], ypT (HR ¼ 1.65, P ¼ 0.005), and ypN (HR ¼ 1.62, P ¼ 0.004) were independent prognostic factors.'' Again, we thank Drs. Chen, Wen, and Zheng.